Propanc Biopharma Inc.
PPCB | NASDAQ
$1.92
+$0.08 (+4.35%)
Nov 2, 2026, 12:00 PM ET · Market open
Fiscal Year Period Ending | FY 2026 Jun 30, 2026 | FY 2025 Jun 30, 2025 | FY 2024 Jun 30, 2024 | FY 2023 Jun 30, 2023 | FY 2022 Jun 30, 2022 | FY 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|
PE Ratio | -0.09 | -0.28 | -823.65K | -0.08 | -0.08 | -0.06 |
PEG Ratio | 0 | 0 | 8.24K | 0 | 0 | 0 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 0.18 | 1.18 | -438.84K | -0.08 | -0.08 | -0.05 |
P/FCF Ratio | -0.30 | -40.65 | -1.77M | -0.21 | -0.18 | -0.14 |
P/OCF Ratio | -0.30 | -40.65 | -1.77M | -0.21 | -0.18 | -0.14 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | 0.01 | 0.12 | -0.25 | -0.18 | -0.34 | -0.22 |
Quick Ratio | 2.55 | 1.50 | 0.01 | 0.01 | 0 | 0 |
Current Ratio | 2.55 | 1.50 | 0.01 | 0.01 | 0 | 0 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | -42.24 | -101.60 | -2.31 | -3.33 | -3.50 | -4.03 |
Return on Equity | -200.63% | -423.72% | 48.17% | 85.35% | 87.91% | 66.05% |
Return on Assets | -147.60% | -300.14% | -2.52K% | -4.41K% | -3.26K% | -15.46K% |
Return on Invested Capital | -192.44% | -366.39% | 50.67% | 65.88% | 98.36% | 71.89% |
Dividend Yield | 55.31% | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | -4.94% | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | -16.41% | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove PPCB